BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38151011)

  • 21. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
    Zhao HJ; Li Y; Liu SM; Sun XG; Li M; Hao Y; Cui LQ; Wang AH
    Ren Fail; 2016 Jul; 38(6):849-56. PubMed ID: 27055479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
    Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
    J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
    Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L
    Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study.
    Shen JI; Saxena AB; Vangala S; Dhaliwal SK; Winkelmayer WC
    BMC Nephrol; 2017 Jun; 18(1):196. PubMed ID: 28623899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renin-angiotensin-aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system.
    Sandhu AT; Kohsaka S; Lin S; Woo CY; Goldstein MK; Heidenreich PA
    Am Heart J; 2021 Oct; 240():46-57. PubMed ID: 34126079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure.
    Kim HJ; Jo SH; Lee MH; Seo WW; Choi JO; Ryu KH
    Adv Ther; 2020 Sep; 37(9):3839-3849. PubMed ID: 32676928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease.
    Magvanjav O; Cooper-DeHoff RM; McDonough CW; Gong Y; Segal MS; Hogan WR; Johnson JA
    J Clin Hypertens (Greenwich); 2019 Jan; 21(1):91-101. PubMed ID: 30427124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis.
    Liu Q; Fu W; Zhu CJ; Ding ZH; Dong BB; Sun BQ; Chen RC
    BMC Infect Dis; 2023 Jan; 23(1):53. PubMed ID: 36694122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury.
    Gayat E; Hollinger A; Cariou A; Deye N; Vieillard-Baron A; Jaber S; Chousterman BG; Lu Q; Laterre PF; Monnet X; Darmon M; Leone M; Guidet B; Sonneville R; Lefrant JY; Fournier MC; Resche-Rigon M; Mebazaa A; Legrand M;
    Intensive Care Med; 2018 May; 44(5):598-605. PubMed ID: 29766216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
    Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial.
    Bainey KR; Rahim S; Etherington K; Rokoss ML; Natarajan MK; Velianou JL; Brons S; Mehta SR;
    Am Heart J; 2015 Jul; 170(1):110-6. PubMed ID: 26093871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
    Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC
    PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological interventions for heart failure in people with chronic kidney disease.
    Lunney M; Ruospo M; Natale P; Quinn RR; Ronksley PE; Konstantinidis I; Palmer SC; Tonelli M; Strippoli GF; Ravani P
    Cochrane Database Syst Rev; 2020 Feb; 2(2):CD012466. PubMed ID: 32103487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.
    Whitlock R; Leon SJ; Manacsa H; Askin N; Rigatto C; Fatoba ST; Farag YMK; Tangri N
    Nephrol Dial Transplant; 2023 Oct; 38(11):2503-2516. PubMed ID: 37309038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
    Wang PT; Huang YB; Lin MY; Chuang PF; Hwang SJ
    Kaohsiung J Med Sci; 2012 Sep; 28(9):477-83. PubMed ID: 22974666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury.
    Brar S; Ye F; James MT; Hemmelgarn B; Klarenbach S; Pannu N;
    JAMA Intern Med; 2018 Dec; 178(12):1681-1690. PubMed ID: 30422153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure.
    Soler MJ; Noordzij M; Abramowicz D; de Arriba G; Basile C; van Buren M; Covic A; Crespo M; Duivenvoorden R; Massy ZA; Ortiz A; Sanchez JE; Petridou E; Stevens K; White C; Vart P; Gansevoort RT;
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):1061-1072. PubMed ID: 34088718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating prescription of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in patients with diabetes and albuminuria.
    Chienwichai K; Chaloemwa P; Sangkaew S; Chang A
    Clin Nephrol; 2024 Jun; 101(6):277-286. PubMed ID: 38606848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accepting Medication Therapy Management Recommendations to Add ACEIs or ARBs in Diabetes Care.
    Hurwitz JT; Grizzle AJ; Augustine J; Rehfeld R; Wild A; Abraham I
    J Manag Care Spec Pharm; 2016 Jan; 22(1):40-8. PubMed ID: 27015050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.